First Manhattan’s Aimmune Therapeutics AIMT Stock Holding History

First Manhattan’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,023,979	Closed	-$17.1M	–	1513
2020 Q2	$17.1M	Buy	+1,023,979	New	+$17.4M	0.1%	104

Other funds holding AIMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Manhattan's AIMT Position: Q3 2020 in Review

First Manhattan sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 1,023,979 shares — an estimated $17.1M sold.

First Manhattan first reported a position in AIMT in Q2 2020 and held it in 1 quarter. The position peaked at $17.1M in Q2 2020. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

First Manhattan reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
First Manhattan sold 1,023,979 Aimmune Therapeutics shares in Q3 2020, an estimated $17.1M.
First Manhattan first reported a position in Aimmune Therapeutics in Q2 2020 and held it in 1 quarter.
First Manhattan's Aimmune Therapeutics position peaked at $17.1M in Q2 2020.
188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on First Manhattan's 13F filing for Q3 2020, filed 12 Nov 2020.